Cohance Lifesciences Ltd vs Curis Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 454.6 as of 05 May 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Curis Lifesciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Curis Lifesciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Cohance Lifesciences Ltd for the Dec '25 is ₹ 550.71 crore as compare to the Sep '25 revenue of ₹ 571.17 crore. This represent the decline of -3.58% The revenue of Curis Lifesciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Cohance Lifesciences Ltd for the Dec '25 is ₹ 96.65 crore as compare to the Sep '25 ebitda of ₹ 136.55 crore. This represent the decline of -29.22% The ebitda of Curis Lifesciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 29.02 crore over 7 quarters. This represents a CAGR of -42.04% The net profit of Curis Lifesciences Ltd changed from ₹ 1.2 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Curis Lifesciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Curis Lifesciences Ltd

Curis Lifesciences Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name and style of 'M/s Loreto Pharmaceutacals', pursuant to a Deed of Partnership dated 2 June, 2010.
Thereafter ' M/s Loreto Pharmaceutacals' was converted from Partnership Firm to a Private Limited Company as 'Curis Lifesciences Private Limited' and received a Certificate of Incorporation dated on March 23rd, 2016 issued by Registrar of Companies, Ahmedabad.
Subsequently, Company was converted into a Public Limited Company and the name of the Company was changed from 'Curis Lifesciences Private Limited' to 'Curis Lifesciences Limited' vide certified incorporated upon the conversion dated August 9, 2024, issued by the Central Processing Centre, Manesar. Company's business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic.

FAQs for the comparison of Cohance Lifesciences Ltd and Curis Lifesciences Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Curis Lifesciences Ltd?

Market cap of Cohance Lifesciences Ltd is 17,391 Cr while Market cap of Curis Lifesciences Ltd is 97 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Curis Lifesciences Ltd?

The stock performance of Cohance Lifesciences Ltd and Curis Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Curis Lifesciences Ltd?

As of May 5, 2026, the Cohance Lifesciences Ltd stock price is INR ₹454.6. On the other hand, Curis Lifesciences Ltd stock price is INR ₹121.0.

How do dividend payouts of Cohance Lifesciences Ltd and Curis Lifesciences Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Curis Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.